Takita Takako, Furuhashi Mitsuyoshi, Fujimoto Taiki, Suzuki Hiroo, Harada Masaki, Maruyama Satoshi, Tamiya Rika, Kamiya Eri, Okamoto Mari, Tukada Atsuyo, Furuhashi Mikako, Kato Akihiko
Department of Internal Medicine, Maruyama Hospital, Shizuoka, Japan.
Ther Apher Dial. 2014 Jun;18 Suppl 1:18-22. doi: 10.1111/1744-9987.12199.
Lanthanum carbonate (LC) is available in the two formulations of chewable tablets and granules. In this study, we changed the formulation of LC from chewable tablet to granules, and compared the laboratory parameters for 3 months before and after changing formulation in 58 hemodialysis (HD) patients. We also surveyed patients about their preferences for the two formulations. The mean serum phosphorus (P) levels decreased significantly (P < 0.01) from 6.7 mg/dL to 6.4 mg/dL after the change. The levels for serum albumin and geriatric nutritional risk index increased significantly (P < 0.01). Serum calcium levels also increased significantly (P < 0.01), while serum intact parathyroid hormone levels decreased significantly (P < 0.01). In the survey, approximately half of the patients responded that the granules were easier to take than the chewable tablets. These findings suggest that changing the formulation of LC to granules may reduce serum P levels of the HD patients in clinical practices.
碳酸镧（LC）有咀嚼片和颗粒剂两种剂型。在本研究中，我们将LC的剂型从咀嚼片改为颗粒剂，并比较了58例血液透析（HD）患者在剂型改变前后3个月的实验室参数。我们还就患者对这两种剂型的偏好进行了调查。改变剂型后，血清磷（P）平均水平从6.7mg/dL显著降至6.4mg/dL（P<0.01）。血清白蛋白水平和老年营养风险指数显著升高（P<0.01）。血清钙水平也显著升高（P<0.01），而血清完整甲状旁腺激素水平显著降低（P<0.01）。在调查中，约一半的患者表示颗粒剂比咀嚼片更易于服用。这些结果表明，在临床实践中，将LC剂型改为颗粒剂可能会降低HD患者的血清P水平。
Zotero 插件